Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 2/2018

01-04-2018 | Review

Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action

Authors: Jonathan Jia Yuan Ong, Milena De Felice

Published in: Neurotherapeutics | Issue 2/2018

Login to get access

Abstract

Migraine is a common and disabling primary headache disorder with a significant socioeconomic burden. The management of migraine is multifaceted and is generally dichotomized into acute and preventive strategies, with several treatment modalities. The aims of acute pharmacological treatment are to rapidly restore function with minimal recurrence, with the avoidance of side effects. The choice of pharmacological treatment is individualized, and is based on the consideration of the characteristics of the migraine attack, the patient’s concomitant medical problems, and treatment preferences. Notwithstanding, a good understanding of the pharmacodynamic and pharmacokinetic properties of the various drug options is essential to guide therapy. The current approach and concepts relevant to the acute pharmacological treatment of migraine will be explored in this review.
Appendix
Available only for authorised users
Literature
1.
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-1602.CrossRef
2.
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646-657.PubMedCrossRef
3.
Cooke LJ, Becker WJ. Migraine prevalence, treatment and impact: the canadian women and migraine study. Can J Neurol Sci. 2010;37(5):580-587.PubMedCrossRef
4.
Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013;40(5 Suppl. 3):S1-S80.PubMedCrossRef
5.
Headache Classification Committee of the International Headache Society (HIS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629-808.CrossRef
6.
Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: an electronic diary study. Neurology. 2003;60(6):935-940.PubMedCrossRef
7.
Kelman L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache. 2004;44(9):865-872.PubMedCrossRef
8.
9.
Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia. 1992;12(4):221-228.PubMedCrossRef
10.
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553-622.PubMedPubMedCentralCrossRef
11.
Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011;12(10):570-584.PubMedCrossRef
12.
13.
14.
Noseda R, Borsook D, Burstein R. Neuropeptides and neurotransmitters that modulate thalamo-cortical pathways relevant to migraine headache. Headache. 2017;57(Suppl. 2):97-111.PubMedPubMedCentralCrossRef
15.
Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754-762.PubMedCrossRef
16.
Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012;32(1):6-38.PubMedCrossRef
17.
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20.PubMedCrossRef
18.
Lipton RB, Stewart WF, Stone AM, Lainez MJ, Sawyer JP, Disability in Strategies of Care Study group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA. 2000;284(20):2599-2605.PubMedCrossRef
19.
Sculpher M, Millson D, Meddis D, Poole L. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. Pharmacoeconomics. 2002;20(2):91-100.PubMedCrossRef
20.
Ahrens SP, Farmer MV, Williams DL, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia. 1999;19(5):525-530.PubMedCrossRef
21.
Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013(4):CD008041.
22.
Geraud G, Compagnon A, Rossi A; COZAM Study Group. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol. 2002;47(2):88-98.PubMedCrossRef
23.
Schulman EA, Dermott KF. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache. 2003;43(7):729-733.PubMedCrossRef
24.
Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet. 1995;346(8980):923-926.PubMedCrossRef
25.
Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968-981.PubMedCrossRef
26.
MacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia. 1993;13(2):124-127.PubMedCrossRef
27.
Doggrell SA, Hancox JC. Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine. Expert Opin Drug Saf. 2014;13(1):131-138.PubMedCrossRef
28.
Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs. 2003;17(9):653-667.PubMedCrossRef
29.
Jones EB, Gonzalez ER, Boggs JG, Grillo JA, Elswick RK, Jr. Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med. 1994;24(2):237-241.PubMedCrossRef
30.
The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325(5):316-321.CrossRef
31.
Tepper SJ, Chen S, Reidenbach F, Rapoport AM. Intranasal zolmitriptan for the treatment of acute migraine. Headache. 2013;53(Suppl. 2):62-71.PubMedCrossRef
32.
Diener HC, Montagna P, Gacs G, et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26(5):537-547.PubMedCrossRef
33.
Kellstein DE, Lipton RB, Geetha R, et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia. 2000;20(4):233-243.PubMedCrossRef
34.
Lange R, Schwarz JA, Hohn M. Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2000;20(7):663-667.PubMed
35.
Freitag F, Smith T, Mathew N, et al. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. Headache. 2008;48(3):341-354.PubMedCrossRef
36.
Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia. 2005;25(9):735-742.PubMedCrossRef
37.
Lipton RB, Munjal S, Buse DC, et al. Allodynia is associated with initial and sustained response to acute migraine treatment: results from the American Migraine Prevalence and Prevention Study. Headache. 2017;57(7):1026-1040.PubMedCrossRef
38.
Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008;28(4):383-391.PubMedCrossRef
39.
Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia. 1994;14(5):330-338.PubMedCrossRef
40.
Thorlund K, Mills EJ, Wu P, et al. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia. 2014;34(4):258-267.PubMedCrossRef
41.
Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43(4):376-388.PubMedCrossRef
42.
Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007;297(13):1443-1454.PubMedCrossRef
43.
Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45(8):983-991.PubMedCrossRef
44.
Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol. 1996;53(2):180-184.PubMedCrossRef
45.
Thompson MR. The active constituents of ergot: a pharmacological and chemical study. J Am Pharm Assoc 1935;24(1):24-38.
46.
Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006;46(Suppl. 4):S171-S181.PubMedCrossRef
47.
Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33(1):48-56.PubMedCrossRef
48.
Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia. 1988;8(2):83-91.PubMedCrossRef
49.
Muller-Schweinitzer E. Venoconstrictor responses to dihydroergocristine and dihydroergotamine: evidence for the involvement of 5-HT1 like receptors. Cardiovasc Drugs Ther. 1990;4(6):1455-1460.PubMedCrossRef
50.
Muller-Schweinitzer E, Rosenthaler J. Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs. J Cardiovasc Pharmacol. 1987;9(6):686-693.PubMedCrossRef
51.
Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium. Headache. 2012;52(1):114-128.PubMedCrossRef
52.
53.
54.
Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827-1832.PubMedCrossRef
55.
Horton BT PG, Blumenthal LS. A new product in the treatment of migraine: a preliminary report. Proc Staff Meet Mayo Clin. 1945;20:241-248.
56.
Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986;26(4):168-171.PubMedCrossRef
57.
Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36(7):995-997.PubMedCrossRef
58.
Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Neurology. 1995;45(3 Pt 1):577-584.PubMedCrossRef
59.
60.
Shrewsbury SB, Cook RO, Taylor G, Edwards C, Ramadan NM. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler. Headache. 2008;48(3):355-367.PubMedCrossRef
61.
Stoll A. Zur Kenntnis der Mutterkornalkaloid. Verb, schweiz. Naturf. Ges., Neuenburg, 1920;101:190-191.
62.
Maier HW. L’ergotamine, inhibiteur du sympathique étudié en clinique, comme moyen d’exploration et comme agent thérapeutique. Rev Neurol. 1926;33:1104–8.
63.
Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. 2000;123 (Pt 1):9-18.PubMedCrossRef
64.
Sanders SW, Haering N, Mosberg H, Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol 1986;30(3):331-334.PubMedCrossRef
65.
Tfelt-Hansen PJE. Ergotamine. In: Olesen JT-HP, Welch KM, editor. The headaches. New York: Raven Press; 1993. p. 313-322.
66.
A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. Eur Neurol. 1991;31(5):314-322.
67.
Johnston BM, Saxena PR. The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol. 1978;63(3):541-549.PubMedPubMedCentralCrossRef
68.
De Vries P, Villalon CM, Heiligers JP, Saxena PR. Characterization of 5-HT receptors mediating constriction of porcine carotid arteriovenous anastomoses; involvement of 5-HT1B/1D and novel receptors. Br J Pharmacol. 1998;123(8):1561-1570.PubMedPubMedCentralCrossRef
69.
Cortijo J, Marti-Cabrera M, Bernabeu E, et al. Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies. Br J Pharmacol. 1997;122(7):1455-1463.PubMedPubMedCentralCrossRef
70.
Muller-Schweinitzer E, Fanchamps A. Effects on arterial receptors of ergot derivatives used in migraine. Adv Neurol. 1982;33:343-356.PubMed
71.
MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998;98(1):25-30.PubMedCrossRef
72.
Galer BS, Lipton RB, Solomon S, Newman LC, Spierings EL. Myocardial ischemia related to ergot alkaloids: a case report and literature review. Headache. 1991;31(7):446-450.PubMedCrossRef
73.
Saxena PR, Ferrari MD. 5-HT(1)-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 1989;10(5):200-204.PubMedCrossRef
74.
Hargreaves RJ, Shepheard SL. Pathophysiology of migraine—new insights. Can J Neurol Sci. 1999;26(Suppl. 3):S12-S19.PubMedCrossRef
75.
76.
Humphrey PP, Feniuk W, Perren MJ, Connor HE, Oxford AW. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia. 1989;9(Suppl. 9):23-33.PubMed
77.
Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET. Serotonin and migraine. Ann N Y Acad Sci 1990;600:587-598.PubMedCrossRef
78.
Humphrey PP, Feniuk W, Perren MJ. Anti-migraine drugs in development: advances in serotonin receptor pharmacology. Headache. 1990;30(1 Suppl):12-16.PubMedCrossRef
79.
Humphrey PP, Feniuk W, Marriott AS, Tanner RJ, Jackson MR, Tucker ML. Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol. 1991;31(5):282-290.PubMedCrossRef
80.
Humphrey PP, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991;12(12):444-446.PubMedCrossRef
81.
Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review. Cephalalgia. 2004;24(5):321-332.PubMedCrossRef
82.
Rapoport AM, Tepper SJ, Sheftell FD, Kung E, Bigal ME. Which triptan for which patient? Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2006;27(Suppl. 2):S123-S129.CrossRef
83.
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358(9294):1668-1675.PubMedCrossRef
84.
Farkkila M, Olesen J, Dahlof C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia. 2003;23(6):463-471.PubMedCrossRef
85.
Tepper SJ, Donnan GA, Dowson AJ, et al. A long-term study to maximise migraine relief with zolmitriptan. Curr Med Res Opin 1999;15(4):254-271.PubMedCrossRef
86.
Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414-425.PubMedCrossRef
87.
Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD. The triptan formulations: how to match patients and products. CNS Drugs. 2003;17(6):431-447.PubMedCrossRef
88.
Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache. 2010;50(2):264-272.PubMedCrossRef
89.
Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010;50(6):1089-1099.PubMedCrossRef
90.
Artto V, Nissila M, Wessman M, Palotie A, Farkkila M, Kallela M. Treatment of hemiplegic migraine with triptans. Eur J Neurol. 2007;14(9):1053-1056.PubMedCrossRef
91.
Klapper J, Mathew N, Nett R. Triptans in the treatment of basilar migraine and migraine with prolonged aura. Headache. 2001;41(10):981-984.PubMedCrossRef
92.
Russell MB, Ducros A. Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol 2011;10(5):457-470.PubMedCrossRef
93.
Pelzer N, Stam AH, Haan J, Ferrari MD, Terwindt GM. Familial and sporadic hemiplegic migraine: diagnosis and treatment. Curr Treat Options Neurol 2013;15(1):13-27.PubMedCrossRef
94.
Silberstein SD, Stirpe JC. COX inhibitors for the treatment of migraine. Expert Opin Pharmacother 2014;15(13):1863-1874.PubMedCrossRef
95.
Tepper DE. Non-steroidal anti-inflammatories for the acute treatment of migraine. Headache. 2013;53(1):225-226.PubMedCrossRef
96.
Suthisisang C, Poolsup N, Kittikulsuth W, Pudchakan P, Wiwatpanich P. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother 2007;41(11):1782-1791.PubMedCrossRef
97.
Suthisisang CC, Poolsup N, Suksomboon N, Lertpipopmetha V, Tepwitukgid B. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache. 2010;50(5):808-818.PubMedCrossRef
98.
Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013(4):CD008783.
99.
Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013(4):CD008039.
100.
Lipton RB, Grosberg B, Singer RP, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia. 2010;30(11):1336-1345.PubMedCrossRef
101.
Law S, Derry S, Moore RA. Naproxen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013(10):CD009455.
102.
103.
Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol 2007;254(6):705-712.PubMedCrossRef
104.
Graham GG, Scott KF. Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-413.PubMedCrossRef
105.
Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med 2000;160(22):3486-3492.PubMedCrossRef
106.
Diener HC, Pfaffenrath V, Pageler L, Peil H, Aicher B. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2005;25(10):776-787.PubMedCrossRef
107.
Derry S, Moore RA, McQuay HJ. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010(11):CD008040.
108.
Tfelt-Hansen P, Olesen J. Paracetamol (acetaminophen) versus acetylsalicylic acid in migraine. Eur Neurol. 1980;19(3):163-165.PubMedCrossRef
109.
Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006;296(1):87-93.PubMedCrossRef
110.
Silberstein SD, Freitag FG, Rozen TD, et al. Tramadol/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial. Headache. 2005;45(10):1317-1327.PubMedCrossRef
111.
Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol 2012;14(1):27-35.PubMedCrossRef
112.
Barbanti P, Fofi L, Aurilia C, Egeo G. Dopaminergic symptoms in migraine. Neurol Sci 2013;34(Suppl. 1):S67-S70.PubMedCrossRef
113.
Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ 2004;329(7479):1369-1373.PubMedPubMedCentralCrossRef
114.
Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med 2002;23(2):141-148.PubMedCrossRef
115.
Shrestha M, Singh R, Moreden J, Hayes JE. Ketorolac vs chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Arch Intern Med 1996;156(15):1725-1728.PubMedCrossRef
116.
Jones J, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA 1989;261(8):1174-1176.PubMedCrossRef
117.
Donaldson D, Sundermann R, Jackson R, Bastani A. Intravenous dexamethasone vs placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blinded, placebo-controlled randomized clinical trial. Am J Emerg Med 2008;26(2):124-130.PubMedCrossRef
118.
Rowe BH, Colman I, Edmonds ML, Blitz S, Walker A, Wiens S. Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache. Headache. 2008;48(3):333-340.PubMedCrossRef
119.
Fiesseler FW, Shih R, Szucs P, et al. Steroids for migraine headaches: a randomized double-blind, two-armed, placebo-controlled trial. J Emerg Med 2011;40(4):463-468.PubMedCrossRef
120.
Friedman BW, Greenwald P, Bania TC, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007;69(22):2038-2044.PubMedCrossRef
121.
Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications. Headache. 2012;52(3):467-482.PubMedCrossRef
122.
Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine. Pain. 2009;142(3):179-182.PubMedCrossRef
123.
Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71(22):1821-1828.PubMedCrossRef
124.
Ho TW, Rodgers A, Bigal ME. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache. 2009;49(3):100-403.CrossRef
125.
Aurora SK, Barrodale PM, McDonald SA, Jakubowski M, Burstein R. Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache. 2009;49(7):1001-4.PubMedPubMedCentralCrossRef
126.
Becker WJ. Acute Migraine Treatment. Continuum (Minneap Minn). 2015;21(4 Headache):953-972.
127.
Diener HC, Peil H, Aicher B. The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: a post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2011;31(14):1466-1476.PubMedCrossRef
128.
129.
MacGregor EA, Victor TW, Hu X, et al. Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache. 2010;50(4):528-538.PubMedCrossRef
130.
Mannix LK, Loder E, Nett R, et al. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007;27(5):414-421.PubMedCrossRef
131.
Tuchman M, Hee A, Emeribe U, Silberstein S. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006;20(12):1019-1026.PubMedCrossRef
132.
Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology. 2008;70(17):1555-1563.PubMedCrossRef
133.
134.
Mannix LK, Martin VT, Cady RK, et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol 2009;114(1):106-113.PubMedCrossRef
135.
Bigal M, Sheftell F, Tepper S, Tepper D, Ho TW, Rapoport A. A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache. 2008;48(9):1286-1293.PubMedCrossRef
136.
Nezvalova-Henriksen K, Spigset O, Nordeng H. Effects of codeine on pregnancy outcome: results from a large population-based cohort study. Eur J Clin Pharmacol 2011;67(12):1253-1261.PubMedPubMedCentralCrossRef
137.
MacGregor EA. Pharmacological management of migraine in pregnancy. In: Mitsikostas DD, Paemeleire K, editors. Pharmacological Management of Headaches. Switzerland: Springer International Publishing; 2016. p. 155-166.
138.
Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003;327(7411):368.PubMedPubMedCentralCrossRef
139.
Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother 2006;40(5):824-829.PubMedCrossRef
140.
Ephross SA, Sinclair SM. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. Headache. 2014;54(7):1158-1172.PubMedCrossRef
141.
Nezvalova-Henriksen K, Spigset O, Nordeng H. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study. Headache. 2010;50(4):563-575.PubMedCrossRef
142.
Kallen B, Nilsson E, Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf. 2011;34(8):691-703.PubMedCrossRef
143.
Daniel S, Koren G, Lunenfeld E, Bilenko N, Ratzon R, Levy A. Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortions. CMAJ 2014;186(5):E177-E182.PubMedPubMedCentralCrossRef
144.
Ward RM BB, Benitz WE, Burchfield DJ, et al. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108 (3):776-789.CrossRef
145.
Hendrickson RG, McKeown NJ. Is maternal opioid use hazardous to breast-fed infants? Clin Toxicol (Phila). 2012;50(1):1-14.PubMedCrossRef
146.
Akerman S, Romero-Reyes M. Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine. Expert Rev Neurother. 2013;13(9):1041-1059.PubMedCrossRef
147.
Mathew NT, Loder EW. Evaluating the triptans. Am J Med 2005;118(Suppl. 1):28s-35s.PubMed
148.
Bigal ME, Bordini CA, Antoniazzi AL, Speciali JG. The triptan formulations: a critical evaluation. Arq Neuropsiquiatr 2003;61(2a):313-320.PubMedCrossRef
149.
Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 2001;40(3):189-205.PubMedCrossRef
150.
Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340(24):1888-1899.PubMedCrossRef
Metadata
Title
Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action
Authors
Jonathan Jia Yuan Ong
Milena De Felice
Publication date
01-04-2018
Publisher
Springer International Publishing
Published in
Neurotherapeutics / Issue 2/2018
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-017-0592-1

Other articles of this Issue 2/2018

Neurotherapeutics 2/2018 Go to the issue

Original Article

Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson’s Disease

Correction

Correction to: Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action

Review

Targeted Nitric Oxide Synthase Inhibitors for Migraine

Original Article

Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy—a Prospective Follow-Up

Original Article

Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial

Review

Targeted Acid-Sensing Ion Channel Therapies for Migraine